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Abstract 
Background: Malaria can be transmitted by blood transfusion from human to human and it is responsible for the 
majority of transfusion-transmitted infectious diseases worldwide. In sub-Saharan Africa, it had been estimated that 
almost a quarter of blood donations contain malaria parasites. Since rapid diagnostic tests and thick blood smear 
microscopy lack sensitivity for low density parasitaemia, particularly in asymptomatic adults, the most reliable method 
to assess the problem of transfusion-transmitted malaria are nucleic acid-based molecular approaches such as quanti-
tative polymerase chain reaction. The study was undertaken to determine the prevalence of sub-microscopic malaria 
parasite infection among blood donors in Malabo, Equatorial Guinea.
Methods: Between July and August 2017, a total of 200 individual blood samples from blood donors at the Malabo 
Blood Bank were collected and screened by rapid diagnostic tests and thick blood smear microscopy. Retrospectively, 
the same samples were analysed for the presence of undetected, low-density malaria parasites using quantitative 
polymerase chain reaction.
Results: In comparison to 6.5% (13/200) by rapid diagnostic test and 2.0% (4/200) by microscopy, the proportion of 
Plasmodium falciparum positive blood donations analysed by quantitative polymerase chain reaction was significantly 
higher (26%, 52/200). Densities of P. falciparum positive blood donations were ranging from 0.06 to 3707.0 parasites/
µL with 79.6% below 100 parasites/µL and therefore not detectable by non-molecular malaria diagnostic tests. qPCR 
based species identification revealed that P. falciparum was the dominating species responsible for 88.1% (52/59) of 
positive blood donations, followed by Plasmodium malariae (15.3%, 9/59) and Plasmodium ovale (3.4%, 2/59).
Conclusions: This study confirms that in malaria endemic settings, sub-patent malaria infections among blood 
donors are prevalent. In blood collected from healthy donors living in Malabo, P. falciparum, P. malariae and P. ovale 
parasites were identified. Currently widely used malaria diagnostic tools have missed more than 75% of P. falciparum 
containing blood donations, demonstrating the value of quantitative polymerase chain reaction to reliably detect 
low density P. falciparum infections. Since the availability of molecular diagnostic methods in malaria endemic 
countries is still limited, the blood recipients living in malaria endemic countries should be treated following WHO 
recommendations.
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Background
Malaria is a vector-borne parasitic tropical disease found 
in 55 countries globally [1]. Six Plasmodium species are 
known to infect humans including Plasmodium falcipa-
rum, Plasmodium vivax, Plasmodium malariae, Plas-
modium ovale curtisi, Plasmodium ovale wallikeri and 
Plasmodium knowlesi [2]. Malaria is transmitted to the 
human host through the bite of a female Anopheles mos-
quito when the sporozoite stage is inoculated during the 
feeding. The parasite undergoes a pre-erythrocytic liver 
stage reproduction that is clinically silent and lasts 1 to 
2 weeks before the release of merozoites into the blood-
stream. These merozoites rapidly infect red blood cells, 
starting the asexual blood stage whereby the parasite 
undergoes cycles of asexual replication that include the 
ring, trophozoite, and schizont stages leading to regular 
fever episodes [2]. In adult human populations living in 
malaria endemic countries, the prevalence of sub-patent 
malaria infections is up to 80% [3] with certain parasite 
clones surviving in the human host more than 300 days 
[4].
Diagnosis of malaria is performed in blood samples 
collected from potentially infected humans. The gold 
standard for malaria diagnosis remains light microscopy 
of stained blood smears. Thick blood smears provide 
sensitivity and thin smears allow the identification of dif-
ferent malaria species and the quantitation of infection 
[5]. Rapid diagnostic tests (RDTs) are widely used since 
they offer less dependence on the availability of labora-
tory infrastructure, and can also be employed by inex-
perienced health workers [6]. RDTs are often based on 
parasite-derived histidine-rich protein 2 (PfHRP2) for 
sensitive and specific detection of P. falciparum, and lac-
tate dehydrogenase enzyme (LDH) or aldolase for a Pan-
Plasmodium detection of all human infective malaria 
species [7]. The lower limit of detection (LOD) for 
microscopy is between 50 and 500 parasites/µL depend-
ing on the expertise of the microscopist [5] and 100 para-
site/µL for the PfHRP2 based P. falciparum RDTs [8]. 
Differential diagnosis of P. ovale, P. malariae, P. vivax and 
P. knowlesi is hampered by the low density blood stage 
infections and the difficulty in distinguishing these spe-
cies based on morphology of trophozoites using micros-
copy [9].
Nucleic acid amplification technologies (NATs) are 
more expensive and require advanced laboratory infra-
structure but provide much better sensitivity. The 
parasites’ multi-copy 18S small subunit ribosomal deox-
yribonucleic acid (rDNA) and/or its highly expressed 
ribonucleic acid (rRNA) is the most frequently used bio-
marker for NATs [10]. Different methods for 18S rDNA/
rRNA detection are currently in use with a great varia-
tion in sensitivity. Qualitative methods targeting 18S 
rDNA, such as nested polymerase chain reaction (PCR) 
[11] and LAMP [12], reach LODs of 0.1–10 parasites/µL. 
The use of quantitative PCR (qPCR) [13], does not only 
allow absolute quantification of infections but also lowers 
the LOD to less than 1  parasite/µL. The use of Reverse 
Transcription quantitative PCR (RT-qPCR), amplifying 
total nucleic acids (RNA and DNA) of the 18S genes [14–
16], and qPCR assays targeting alternative multi-copy 
genomic sequences [17] further increase sensitivities of 
NATs. Apart from increased sensitivity of NATs, molecu-
lar detection using PCR has improved species discrimi-
nation compared to either microscopy or RDTs [18].
Screening for transfusion transmitted infections should 
follow the World Health Organization (WHO) recom-
mendations which include searching for chronic infec-
tious diseases including HIV-1, HIV-2, Hepatitis B, 
Hepatitis C and Treponema pallidum (syphillis) [19]. 
Based on the local epidemiological infectious disease 
situation, the WHO recommends that blood donations 
should also be screened for malaria [19, 20]. Malaria 
can be efficiently transmitted by blood transfusion from 
human to human and is undoubtedly responsible for the 
majority of transfusion transmitted diseases in the world 
[21]. The rate of transfusion-transmitted malaria (TTM) 
in malaria endemic sub-Saharan regions is estimated 
between 14 and 28% [22]. Several reports describe that P. 
falciparum [22], P. vivax [23], P. malariae [24], P. knowlesi 
[25] and P. ovale [26] can be transmitted either through 
blood donations or solid organ transplantations.
Malaria species circulating in Equatorial Guinea 
include P. falciparum, P. malariae, P. ovale and P. vivax 
[27–29]. The Bioko Island Malaria Control Project 
(BIMCP) started in 2004 with the aim to reduce malaria 
transmission and to control the burden of disease and 
has received substantial funding from the Government 
of Equatorial Guinea and private donors including Mara-
thon EG Production Limited, Noble Energy, and Atlan-
tic Methanol Production Company. The malaria control 
strategy of the BIMCP rests on vigorous vector control 
measures, effective case management, prevention of 
malaria during pregnancy, behavioural change commu-
nications and regular monitoring and evaluation [30]. 
The BIMCP has had significant success in reducing P. fal-
ciparum parasite prevalence in the 2–14  years old chil-
dren and adolescent from 45% (95% CI 40–50%) in 2004 
(baseline) to 12.1% (95% CI 11.2–13.3%) in 2016 based on 
annual Malaria Indicator Survey (MIS) data [30].
Since RDTs and microscopy lack sensitivity for low-
level parasitaemia, particularly in asymptomatic adults, 
the most reliable method to assess the problem of TTM 
are NATs such as qPCR. This study has set out to analyse 
a selection of 200 blood samples from the blood bank in 
Malabo using qPCR to identify sub-patent P. falciparum 
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infections that cannot be detected by commonly used 
RDTs and microscopy. In addition, the presence of other 
TTM causing Plasmodium species was analysed using a 
newly developed single tube multiplex qPCR assay.
Methods
Study site and participant recruitment
The study was conducted at the Central Blood Bank in 
Malabo on Bioko Island. Bioko Island, located in West-
central Africa and home of Equatorial Guinea’s capi-
tal city Malabo, is 32  km from the coast of Cameroon. 
The approximately 250,000 people, who mainly reside 
in Malabo are at risk of malaria year-round [30]. Adults 
willing to donate blood and who are Hepatitis B, Hepa-
titis C, and HIV negative were eligible for blood dona-
tion. Microscopy and RDT (CareStart™ Malaria HRP2/
pLDH Pf/PAN Combo) were used for malaria screen-
ing at the blood bank and the results were kept at the 
blood bank until the end of qPCR analysis. The Malabo 
Central Blood Bank processes around 100 donors per 
month; the majority being donors assisting friends and 
families during emergency situations, and the remain-
der are donors that voluntarily donate blood on a regular 
basis. The blood bank is run by a public–private coopera-
tion between the Ministry of Health and Social Welfare, 
the University of Valencia Hospital, and funded by the 
AGEM-GUINEA company.
Sample collection for molecular diagnostics
Between July and August 2017, a total of 200 individual 
blood donations from routine visitors were selected to 
conduct this study. 1  mL of whole blood was collected 
in EDTA tubes as part of the usual blood donation pro-
cedures in the blood bank. The blood was immediately 
used for microscopy and RDT, with the remaining blood 
immediately stored at − 20  °C. The samples were trans-
ported in a cooling box to the laboratory of the Equa-
torial Guinea Malaria Vaccine Initiative (EGMVI) in 
Malabo. The laboratory infrastructure of the EGMVI, 
located on the premises of the La Paz Hospital in Malabo, 
which conducted the first clinical trial in the history of 
the country [31], was used for qPCR analysis of the blood 
donations.
The 200 blood samples, from healthy, Hepatitis B, 
Hepatitis C, and HIV-1 and HIV-2 negative blood donors 
were analysed for the presence of possibly undetected, 
low-level malaria parasites using high-sensitive qPCR 
assays. DNA extraction was done manually from 180 µL 
whole blood using Quick-DNA Miniprep kits (Zymo 
Research, Irvine, USA) following manufactures’ guide-
lines and DNA was eluted with 50  µL Elution Buffer. 
DNA samples were kept at − 20  °C prior to qPCR 
analysis.
qPCR for Plasmodium screening and quantification (PlasQ 
assay)
Plasmodium spp. and P. falciparum parasites were quan-
tified using the PlasQ assay. This assay consists of two 
independent Plasmodium targets combined in a multi-
plex assay. The Pan-Plasmodium 18S rDNA sequence 
(Pspp18S) [13, 32], and the P. falciparum-specific acidic 
terminal sequence of the var genes (PfvarATS) [17] were 
used for detection and quantification of parasites. The 
human RNaseP (HsRNaseP) gene served as an internal 
control to assess the quality of DNA extraction and qPCR 
amplification.
Amplification and qPCR measurements were per-
formed using the Bio-Rad CFX96 Real-Time PCR System 
(Bio-Rad Laboratories, California, USA). The thermal 
profile used for PlasQ qPCR is as follows: 60 s at 95  °C; 
45 cycles of 15  s at 95  °C and 45  s at 57  °C. Each reac-
tion contained 2 µL DNA and 8 µL reaction master mix 
containing 1× Luna Universal Probe qPCR Master Mix 
(New England Biolabs, Ipswich, USA) and 1× PlasQ 
Primer Mix (Additional file 1). All qPCR assays were run 
in duplicates with appropriate controls including Non-
Template Control [NTC] and P. falciparum 3D7 DNA 
as positive control [PC]. The mean Cq of the two repli-
cates was reported and in case of one qPCR replicate 
interpreted as malaria positive and the other replicate 
negative, then the assay had to be repeated to arrive at an 
unequivocal result.
Using the first WHO International Standard for P. fal-
ciparum DNA Nucleic Acid Amplification Techniques 
(NIBSC code: 04/176), a serial dilution ranging from 0.05 
to 10,000 parasites/µL was prepared and used for quan-
tification of P. falciparum. The WHO standards were 
run as duplicates in two out of the total 13 qPCR runs 
conducted.
qPCR for Plasmodium species identification (PlasID assay)
Several published [17, 33–37] and unpublished qPCR 
assays, detecting P. falciparum, P. malariae, P. ovale, P. 
vivax and P. knowlesi were evaluated and the best per-
forming primer and probes for each Plasmodium spe-
cies were combined into a new multiplex assay (PlasID). 
The primers and probe combinations used for this novel 
pentaplex malaria qPCR assay is provided in Additional 
file 1.
Amplification and qPCR measurements were per-
formed using the Bio-Rad CFX96 Real-Time PCR System 
(Bio-Rad Laboratories, California, USA). The thermal 
profile used for the PlasID qPCR is as follows: 15 min at 
95 °C; 45 cycles of 15 s at 95 °C and 60 s at 55 °C. Each 
reaction contained 2 µL DNA and 8 µL reaction master 
mix containing 1× HOT  FIREPol® Probe qPCR Mix Plus 
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(Solis Bio Dyne, Tartu, Estonia) and 1× PlasID Primer 
Mix (Additional file  1). All qPCR assays were run in 
duplicates with appropriate controls including Non-Tem-
plate Control [NTC] and DNA of six Plasmodium species 
as positive controls [PC]. DNA controls for P. falciparum, 
P. knowlesi, P. malariae, P. vivax, P. ovale curtisi and P. 
ovale wallikeri were used to evaluate species specificity of 
the PlasID assay. The positive controls were reconfirmed 
by two commercial qPCR assay (GeneFinder™ Malaria 
RealAmp Pf/Pv/Pk and Pf/Pm/Po). Samples with a Cq 
value less than 45 for any of the five Plasmodium targets 
were considered positive for the corresponding Plasmo-
dium species.
Data management and analysis
Geneious version 8.1.9 (Biomatters Ltd, Auckland, New 
Zealand) was used for sequence alignments and oligo-
nucleotide designs. Cq values were obtained from the 
Bio-Rad CFX96 Manager 3.1 software (Bio-Rad Labora-
tories, California, USA) and transferred to a Microsoft 
Access based in-house database designed for storage 
and analysis of qPCR data. Cq values were transformed 
to parasite densities and linked to patient’s metadata col-
lected at the blood bank. Categorical variables were com-
pared by Fisher’s exact test and continuous variables by 
Mann–Whitney using GraphPad Prism version 7.00 for 
Windows (GraphPad Software, La Jolla, USA). P val-
ues < 0.05 were considered to be significant.
Results
Development and implementation of multiplex qPCR 
assays for malaria screening
Two independent qPCR assays were systematically used 
for the screening and identification of malaria parasites. 
The use of two consecutive qPCR assays maximizes the 
amount of information generated by the analysis. The 
first assay (PlasQ), applied to all samples, was designed 
to identify and quantify P. falciparum and/or non-falci-
parum species. Additionally, the internal control serves 
as a general control for quality and performance of the 
DNA extraction and qPCR reaction. The performance 
of the PlasQ assay is shown in Fig. 1a. For both targets, 
PfvarATS and Pspp18S, the Cq values for different par-
asite densities, ranging from 0.05 to 10,000 parasites/
µL were obtained (Pearson r − 0.9969 and − 0.9968, 
respectively). Similar qPCR efficiencies for both targets 
were observed (87.6% and 89.7%). The PfvarATS target 
did detect two additional samples carrying low parasite 
densities (0.1 and 0.05 parasites/µL) resulting in 10 times 
lower LOD compared to the Pspp18S target. The second 
assay (PlasID), which is applied to all Plasmodium spp. 
positive samples, was designed for rapid identification 
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Fig. 1 Analytical performance of PlasQ (a) and PlasID (b) assay. a Correlation of P. falciparum standards and the Cq values for both targets, Pspp18S 
(black circles) and PfvarATS (white circles) of the PlasQ assay. Based on these quadruple replicates of the WHO standards, LODs and qPCR efficiencies 
were calculated. b The ability of the PlasID assay identifying five different malaria species is shown by a representative, composite amplification plot. 
DNA from the six Plasmodium species were analysed in separate tubes during the same qPCR experiment
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of five different malaria causing Plasmodium species. 
Performance of the PlasID assay was assessed using 
well-defined clinical samples as references and this novel 
assay’s ability of identifying P. falciparum, P. malariae, P. 
ovale curtisi, P. ovale wallikeri, P. vivax and P. knowlesi is 
demonstrated in Fig. 1b.
Baseline characteristics of blood donors attended Malabo 
Central Blood Bank
Blood donor characteristics are given in Table  1. All 
donors were Equato-Guineans living in Malabo on Bioko 
Island except two persons, one originating from neigh-
bouring Douala, Cameroon and the other from the 
United States. The majority were male (88.5%) with a 
median age of 32 years, ranging from 18 to 57 years. Sev-
enty-seven donations were from voluntary blood donors 
and 123 donations were from replacement donors, who 
donate blood when required by a member of the patient’s 
family or community (Table 1). Except for the blood pres-
sure, no significant difference in relation to gender, age, 
weight, pulse and anaemia status between these two 
donor groups were observed.
Prevalence of malaria positive blood donations
The flow diagram depicting the sequential malaria diag-
nostic tools applied to the blood donations is summa-
rized in Fig.  2. In the Malabo blood bank, all samples 
were screened using thick blood smear microscopy and 
RDT. Microscopy identified four P. falciparum posi-
tive donations, while RDTs detected 13 malaria positive 
donations. Three donations were positive for both anti-
gens, the P. falciparum specific HRP2 and the Plasmo-
dium spp. LDH antigens. The remaining ten donations 
were positive for HRP2 only. Microscopy and RDT posi-
tive blood donations were not considered for donation 
and were included blinded into this study sample col-
lection on purpose to test the performance of the PlasQ 
assay.
Upon arrival at the EGMVI laboratory all samples were 
screened with the first multiplex qPCR assay (PlasQ), 
targeting P. falciparum (PfvarATS), Plasmodium spp. 
(Pspp18S) and the human RNAseP gene (as an internal 
control). All 200 samples amplified the internal control 
with Cq < 28 and were therefore eligible for further analy-
sis. Over 70% (n = 141) of blood donations were negative 
for any malaria species. Forty-six donations were positive 
for both Plasmodium targets, while six and seven dona-
tions were positive only for P. falciparum or Plasmodium 
spp., respectively. All samples (n = 53) with a positive 
amplification of the Pspp18S target were analysed with 
the species identification assay (PlasID). Apart from con-
firming P. falciparum (n = 33) cases, we also found cases 
of P. malariae (n = 9) and P. ovale (n = 2). Amongst the 
200 blood samples analysed, no P. vivax or P. knowlesi 
was detected.
The assay identified P. malariae or P. ovale in all seven 
samples which were positive for Plasmodium spp. and 
negative for P. falciparum, highlighting the assays abil-
ity to identify non-falciparum species. Compared to the 
PlasQ assay, a reduced sensitivity (71.7%, 33/46) for P. fal-
ciparum detection using the PlasID assay was observed. 
The 13 P. falciparum positive samples missed by the 
PlasID assay had moderate parasitaemia (median of 36.9 
with IQR of 1.3–380.0  parasites/µL) and the five sam-
ples with the highest parasitaemia were positive by RDT. 
None of these samples were positive for any other non-P. 
falciparum species.
An additional 29 malaria negative blood samples were 
also run with the PlasID assay to test specificity of the 
assay. No false positive Plasmodium spp. cases were 
detected, resulting in 100% specificity.
Notably, none of the non-falciparum species had been 
identified by microscopy or RDT. Pan-positive RDTs, 
which detected the Plasmodium spp. LDH, were rather 
associated with higher P. falciparum density than with 
the detection of non-falciparum malaria parasite species. 
The three HRP2 and LDH positive RDTs had a geometric 
mean of 916.3  parasites/µL (range 244.1–3707.0) while 
the nine HRP2 only positive RDTs had a geometric mean 
of 106.0 parasites/µL (range 11.2–543.3) (Table 2).
In summary, 59 blood donations were positive for at 
least one malaria species (29.5%). Plasmodium falcipa-
rum was the dominating species responsible for 88.1% 
of positive blood donations, followed by P. malariae 
(15.3%) and P. ovale (3.4%). Mixed species infections 
were found in 6.8% (4/59) of the malaria positive blood 
donations. One blood donation carried a P. malariae 
and P. ovale co-infection and three donations contained 
Table 1 Comparison of  health characteristics between   
voluntary and replacement donors
a Variables were compared by Fisher’s exact test for categorical variables or 
Mann–Whitney test for continuous variables
b Values expressed as medians with ranges
Voluntary 
donors
Replacement 
donors
P  valuesa
Number of donors 77 123 –
% male 84.4% (65/77) 91.1% (112/123) 0.175
Age in  yearsb 32 [19–55] 32 [18–57] 0.888
Weight in  kgb 73.9 [51–116] 72.0 [52–116.6] 0.593
Blood pressure in 
 mmHgb
126.7 [97.7–169.0] 130.8 [103.6–198.9] 0.035
Pulse in  bpmb 74 [48–101] 73 [51–102] 0.788
Haemoglobin in 
g/dLb
14.6 [12.2–19.6] 14.7 [6.4–18.0] 0.808
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a combination of P. falciparum and P. malariae. The 
observed co-infection proportion between P. falcipa-
rum and P. malariae was slightly higher than expected 
(1.5% versus 1.2%, P = 0.037).
Plasmodium falciparum densities in malaria positive blood 
donations
Data obtained from the PlasQ assay was used to quan-
tify P. falciparum positive blood donations. Para-
site densities calculated based on both targets show a 
high correlation (Spearman r 0.894, Fig.  3). Identified 
non-falciparum species are indicated with green dots. 
Quantification based on the Pspp18S assay revealed, 
that the parasitaemia of these non-falciparum species 
is around or below 10  parasites/µL which was sup-
ported by the high Cq values obtained from the PlasID 
assay. The geometric mean Cq value of the nine P. 
malariae positive samples was 36.9 (range 35.3–39.0) 
and the two positive P. ovale samples had Cq values of 
37.9 and 39.8.
A strong association between the diagnostic tests 
and the parasitaemia in P. falciparum positive blood 
Samples positive for
Pf (n=33), Pm (n=9), Po (n=2), 
Pv (n=0), Pk (n=0)
Samples collected at Blood bank in 
Malabo
n=200
Samples positive 
for Pf only
n=6
Samples positive 
for Pf and Pspp
n=46
Samples positive 
for Pspp only
n=7
Samples negative 
for Pf and Pspp
n=141
Screening and quantification 
of Pf and Pspp by PlasQ assay
(n=200)
Microscopy and RDT screening 
at Blood Bank
Identification of Plasmodium
species by PlasID assay 
(n=53)
Microscopy 
positive
Pf=4
RDT positive
Pf=10
Pan/Pf=3
Fig. 2 Overview of blood sample analysis. Blood donations were systematically screened for the presence of malaria parasites by microscopy, RDT 
and qPCR assays
Table 2 Parasitaemia of blood donations detected with different diagnostic methods
a Quartiles (Median, 25th and 75th percentile)
b Geometric mean and 95% confidence interval
c Pf- and Pf/Pan-RDT results combined
d Pf-RDT results only
e Pf/Pan-RDT results only
Diagnostic tool Median/IQR (parasites/µL)a Geometric mean (parasites/µL)b Range (parasites/µL)
qPCR-PfvarATS 4.6 [0.8–49.0] 5.6 [2.6–12.1] 0.06–3707.0
qPCR-Pspp18S 7.8 [1.3–65.1] 9.5 [4.5–19.8] 0.07–3707.0
RDT  combinedc 134.6 [65.1–536.5] 181.7 [68.98–478.7] 11.16–3707.0
HRP2-RDTd 112.5 [52.2–331.2] 106.0 [42.4–265.1] 11.16–3707.0
HRP2/LDH-RDTe 850.4 [244.1–3707.0] 916.3 [31.11–26990.0] 244.1–3707.0
Microscopy 380.1 [145.4–2909.0] 478.7 [44.03–5205.0] 112.5–3707.0
Page 7 of 11Schindler et al. Malar J            (2019) 18:9 
donations was observed. Non-cumulative parasite den-
sity data grouped by diagnostic test is shown in Fig.  4 
(scatter plot, left y-axis).
In Table 2, the parasite densities grouped by diagnostic 
tool are summarized. Densities of P. falciparum positive 
blood donations ranged from 0.06 to 3707.0 parasites/µL 
with a median of 4.6 parasites/µL (IQR 0.8–49.0), which 
is lower than the LOD for conventional diagnostic tests. 
Only samples with the highest parasitaemia were detect-
able by microscopy (381.1 [145.4–2909.0] parasites/
µL) and RDTs (134.6 [65.1–536.5] parasites/µL), while 
the two qPCR assays detected additional infections with 
lower parasite densities. The median parasitaemia was 
7.8  parasites/µL (IQR 1.3–65.1) for the Pspp18S target 
and 4.6 parasites/µL (IQR 0.8–49.0) for the PfvarATS tar-
get (Table 2).
Performance of diagnostic methods for P. falciparum 
detection in blood donations
In total, 48 previously undetected P. falciparum infec-
tions were identified by conducting the varATS based 
qPCR analysis compared to microscopy, increasing 
the proportion of infected blood donations from 2.0 to 
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26.0%. The detection rate for RDTs and 18S based qPCR 
were 6.5% and 23.0%, respectively (Fig. 4, bar plot, right 
y-axis). This increased detection rate of the qPCR assays 
is also reflected in analytical sensitivities of the diagnostic 
tests. Using the PfvarATS qPCR results as the gold stand-
ard for P. falciparum detection, Pspp18S qPCR (88.5%), 
RDT (23.1%) and microscopy (7.7%) have all reduced sen-
sitivities. Specificities were for all tests above 95%. One 
RDT positive sample could not be confirmed by qPCR, 
while the specificity for Pspp18S was reduced because of 
non-falciparum malaria parasite species, which are also 
detected (Table 3).
Identification of risk factors for malaria positivity
Malaria positive and negative donors were stratified 
according to the differences in the questionnaire that all 
blood donors must fill before proceeding to blood dona-
tion (Additional file  2). The major risk factor for being 
a malaria positive blood donor was reporting fever or 
malaria during the past 3 weeks (Additional file 2). When 
comparing the anthropometric measurements between 
malaria positive and negative donors, marginal differ-
ences in age and weight become apparent (Table 4). An 
increased rate of positive blood donations in replace-
ment donors (29.3%) compared to voluntary donors 
(20.8%) was observed, as well as an increased parasitae-
mia among replacement donors (8.9 versus 2.1 parasites/
µL). However, these differences were not statistically 
significant.
Discussion
This study, conducted in Equatorial Guinea, extends pre-
vious observations of presence of TTM in sub-Saharan 
Africa, and demonstrates the value of NAT approaches to 
reliably detect sub-patent P. falciparum and non-falcipa-
rum malaria parasites including P. malariae and P. ovale. 
Apart from P. falciparum, other malaria causing spe-
cies such as P. vivax, P. malariae, and P. ovale have been 
described to circulate on Bioko Island—similar to neigh-
bouring West African countries [27, 28]. Transfusion of 
any of these malaria species during blood donations have 
the potential to cause severe disease in recipients. In sub-
Saharan Africa, those most at risk are anaemic infants 
and children, pregnant women, or women who suffer 
from high blood losses while giving birth [25, 38, 39]. 
Although, there is a high frequency of TTM in malaria 
endemic regions, the semi-immunity of recipients may 
largely control parasite replication and therefore clinical 
outcome [40].
In malaria non-endemic countries, TTM needs also be 
taken into account to ensure safe blood donations [41]. 
Here, blood the recipients are mainly malaria naïve and 
the immunological control of potentially transfused para-
sites is non-existent resulting in in-creased risk of severe 
malaria disease. P. falciparum parasites have been found 
to survive in blood donations for up to 14 days limiting 
the potential to neutralize malaria during blood donation 
processing and storage [42].
This study demonstrates the challenges blood banks in 
malaria endemic countries encounter. The blood donors 
at the Malabo blood bank were mainly male adults within 
an age range of 18–57 years. Because of their pre-exist-
ing immunity, blood donors of that age tend to have low 
levels of parasites without exhibiting clinical symptoms. 
Ninety-seven percent (97.0%) reported to be in good 
health at the time of blood donations. Apart from self-
reported malaria and/or fever episodes within the last 
3 weeks, no other risk factor had been identified based on 
the provided questionnaire. Since only about 3% (6/198) 
had reported to have malaria and/or fever episodes, the 
use of this risk factor to pre-select blood donors would 
not be very efficient. Deferral of about a quarter of blood 
Table 3 Analytical comparison of methods deployed for P. 
falciparum detection
a Sensitivity and 95% confidence interval
b Specificity and 95% confidence interval
c Positive predictive value and 95% confidence interval
d Negative predictive value and 95% confidence interval
e Specificity and PPV of Pspp18S qPCR assay is reduced because non-falciparum 
Plasmodium species are also detected
Diagnostic tool Sensa Specb PPVc NPVd
qPCR-PfvarATS Gold standard
qPCR-Pspp18S 88.5%
[76.6–95.7]
95.3%
[90.5–98.1]e
86.8%
[76.0–93.2]e
95.9%
[91.7–98.0]
RDT 23.1%
[12.5–36.8]
99.3%
[96.3–99.9]
92.3%
[61.5–100.0]
79.0%
[76.0–81.0]
Microscopy 7.7%
[2.1–18.5]
100.0%
[97.54–100]
100%
–
75.5%
[74.0–76.9]
Table 4 Anthropometric differences in  P. falciparum 
positive versus P. falciparum negative blood donors
a Fisher’s exact test for categorical variables or Mann–Whitney test for 
continuous variables was applied
b Values expressed as medians with ranges
Negative donors Positive donors P  valuesa
Number of donors 148 52 –
% male 86.5% (128/148) 94.2% (49/52) 0.205
Age in  yearsb 33 [18–57] 29 [20–55] 0.013
Weight in  kgb 74.6 [51–116.6] 69.2 [53–110] 0.025
Blood pressure in 
 mmHgb
128.7 [97.7–198.9] 128.3 [100.6–156.9] 0.326
Pulse in  bpmb 74 [48–102] 72 [51–96] 0.519
Haemoglobin in 
g/dLb
14.6 [6.4–19.6] 14.7 [11.6–16.5] 0.319
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donors that are sub-patent malaria carriers in a region 
where blood supply shortage is eminent could be even 
more damaging to public health.
Conventional diagnostic tests are important tools, 
since they are affordable and can be applied immedi-
ately at blood banks, but lack in sensitivity limits their 
usefulness. Microscopy is still an important tool for 
malaria detection since it allows for species identifica-
tion and quantification. The detection limit of an expert 
microscopy is close to 20–50 parasites/µL, but for non-
experienced microscopists, it is up to tenfold higher 
(i.e. 500  parasites/µL) [5]. Currently available RDTs 
are based on detection of circulating, parasite derived 
HRP2, aldolase or lactate dehydrogenase in serum or 
whole blood samples. These RDTs have the ability to 
detect Plasmodium spp. infections with a LOD between 
100 and 1000  parasites/µL which is significantly higher 
when compared to NATs [43]. In addition, there is cur-
rently no single RDT available that could distinguish all 
five malaria species infections posing a clear limitation to 
comprehensive malaria infection status monitoring [44, 
45]. Infections with P. malariae [46], P. ovale [47] and P. 
vivax [48] are usually characterized by low parasitaemia 
levels, rendering these infections largely undetectable by 
using currently available RDT technologies [49].
In this study, more than three-quarter of P. falcipa-
rum and all non-falciparum infections were missed by 
the conventional diagnostic tools. A suitable screening 
method for malaria detection in blood units must have 
high sensitivity, high negative predictive value, must 
include all Plasmodium species, and should be cost effi-
cient. Such a test must enable a reduction of TTM risk, 
as well as that of falsely deferred blood donors found to 
have false positive results.
The PlasQ malaria screening assay applied in this 
study meets some of these requirements. With a LOD of 
0.05 parasites/µL, PlasQ has high sensitivity for P. falci-
parum and includes all other relevant Plasmodium spe-
cies. This assay was extensively used during controlled 
human malaria infections in Tanzanian and Equatorial 
Guinean volunteers and no issues with specificity were 
observed (unpublished). As a limitation, qPCR analysis 
requires an advanced laboratory infrastructure, trained 
personnel and the costs for reagents and consumables for 
this assay is about USD 5, which is higher than the costs 
for RDT or microscopy-based malaria diagnosis.
This study was used to obtain more information about 
non-falciparum malaria species circulating in Malabo. 
Therefore a novel multiplex qPCR assay for parallel 
malaria parasite identification was developed. Using the 
PlasID assay, the main five human infectious malaria spe-
cies can be detected qualitatively in a multiplex assay 
rendering it highly cost efficient since only one DNA 
extraction and qPCR reaction needs to be run. This novel 
malaria species identification assay should be used in 
combination with the PlasQ assay, based on the finding 
that in the PlasID assay, a reduced sensitivity for P. fal-
ciparum is observed. Further development of diagnostic 
assays for the detection of P. malariae and P. ovale, should 
include the ability of species-specific quantification. Esti-
mations based on Pspp18S target of the PlasQ assay, indi-
cate that P. malariae and P. ovale single infections had a 
geometric mean density of about 0.6 parasites/µL, which 
is more than 14 times lower than P. falciparum single 
infections (8.8 parasites/µL).
Educating the general public in malaria endemic 
regions via TV, radio, and pamphlet about the existence 
of TTM and its potential health impact might help to 
raise the awareness of this malaria transmission route, 
both in potential blood donors and medical and nursing 
staff involved in blood transfusions [50]. This study con-
firms prior reports that replacement blood donors are 
particularly prone to harbour sub-patent malaria para-
sites [51]; hence this sub-population of donors are opti-
mal for such awareness campaigns regarding potential 
TTM when donating blood for a family or friend. In addi-
tion to becoming aware of the potential TTM, medical 
and nursing staff should also use anti-malarial interven-
tions when the potential for TTM is high and the malaria 
diagnostic infrastructure is limited. Ultimately, if the goal 
of malaria elimination is pursued vigorously, tackling 
TTM in sub-Saharan Africa needs to be included into the 
malaria elimination agenda.
Conclusions
More than one quarter of blood donations from healthy 
donors living in Malabo were infected with malaria para-
sites. Three species, including P. falciparum, P. malariae 
and P. ovale were detected using two different qPCR 
assays. The majority of these infections were not identi-
fied by the currently widely used malaria diagnostic tools 
such as RDTs and microscopy. Since the availability of 
molecular diagnostic methods in malaria endemic coun-
tries is still limited, the blood recipients living in malaria 
endemic countries should be treated following WHO 
recommendations.
Additional files
Additional file 1. Oligos used in this study.
Additional file 2. Identification of risk factors associated with a malaria 
positive blood donation.
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